ArticleProstate cancer2026
Determinants of the Cost of Illness in Iranian Prostate Cancer Patients.
Article in Prostate cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determinants of the Cost of Illness in Iranian Prostate Cancer Patients.Prostate cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) ranks as the fourth most prevalent form of cancer overall and imposes a substantial financial burden on individuals and communities. Given information on the costs of this disease and the factors influencing them, the present study analyzed factors affecting the costs of medical and nonmedical services for patients with PCa in southern Iran. Methods: Factors affecting the cost of PCa were identified through a scoping review of international databases (ISI Web of Science, Scopus, PubMed, ProQuest, Magiran, and SID) and consultation with PCa experts. Subsequently, data on 254 PCa patients were collected between March 2020 and March 2022 using a two-stage stratified random sampling method. Patients were randomly selected from the provincial Cancer Registry Center lists within strata defined by healthcare catchment areas. Multiple regression analysis using SPSS 13.0 was employed to determine the factors influencing costs. Results: The findings from the multiple regression analysis indicated that premature mortality, grade, and monthly income (all Conclusions: In line with the results, implementing low-cost screening systems for early detection and effective treatment of PCa at all income levels, and directing targeted subsidies to the health sector, especially to low-income patients, can help reduce costs for PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.